UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 4, 2020
Date of Report (Date of earliest event reported)
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38738 | 37-1858472 | ||
| (State of | (Commission | (I.R.S. Employer | ||
| incorporation) | File Number) | Identification Number) |
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7208
(Address of principal executive offices) (Zip code)
(847) 787-7361
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per share | ETON | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item 8.01 Other Events.
On May 4, 2020, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Paul Stickler had joined the Company as its Senior Vice President of Sales and Marketing. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
| Exhibit 99.1 | Press Release dated May 4, 2020 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 4, 2020 | By: | /s/ W. Wilson Troutman |
| W. Wilson Troutman | ||
| Chief Financial Officer and Secretary | ||
| (Principal Financial Officer) |
| 3 |
Exhibit 99.1
Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing
Orphan Drug Expert Paul Stickler to Lead Eton’s Commercialization of Alkindi® Sprinkle and Pediatric Neurology Franchise
DEER PARK, Ill., May 4, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales and Marketing. Stickler brings more than twenty-five years of pharmaceutical sales and marketing experience with a primary focus in orphan and neurology products. In the new role, he will be responsible for the expected launch of Eton’s orphan product Alkindi Sprinkle in the fourth quarter of 2020, as well as the future commercialization of Eton’s pediatric neurology pipeline products.
Prior to joining Eton Pharmaceuticals, Stickler was Vice President of Commercial Operations at Recordati Rare Diseases, a billion-dollar global pharmaceutical company focused on orphan and rare disease products. At Recordati, Paul successfully led sales and marketing activities for numerous orphan drug products including Cystadane, Carbaglu and Panhematin. Before Recordati, Paul held sales and marketing leadership roles at leading pharmaceutical companies including Lundbeck Inc, Ovation Pharmaceuticals and Abbott Laboratories (now AbbVie Inc.).
“Paul’s experience and track record of success commercializing orphan products will make him a valuable addition to our company. Given his background, we believe he is the ideal candidate to lead the launch of Alkindi Sprinkle and the commercialization of our future pediatric neurology products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
“I am truly excited to work at Eton Pharmaceuticals to help build a rare disease and pediatric neurology business. Alkindi will be a great addition for the patient and healthcare communities who know all too well the devastation and hardship adrenal insufficiency can cause,” said Stickler.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products. Eton is primarily focused on hospital injectable and pediatric rare disease products. The company’s first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company’s lead pediatric product is the orphan drug Alkindi® Sprinkle, which is currently under review with the FDA. The company has an additional eight products under development, including three that are under review with the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740